|
Volumn 11, Issue 2, 2009, Pages 81-82
|
The jupiter trial: Key findings, controversies, and implications
|
Author keywords
[No Author keywords available]
|
Indexed keywords
C REACTIVE PROTEIN;
LOW DENSITY LIPOPROTEIN CHOLESTEROL;
PLACEBO;
ROSUVASTATIN;
FLUOROBENZENE;
HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;
PYRIMIDINE DERIVATIVE;
SULFONAMIDE;
CARDIOVASCULAR DISEASE;
CARDIOVASCULAR RISK;
CEREBROVASCULAR ACCIDENT;
CHOLESTEROL BLOOD LEVEL;
CLINICAL TRIAL;
CORONARY ARTERY RECANALIZATION;
DRUG EFFICACY;
HEART INFARCTION;
HUMAN;
MORTALITY;
NOTE;
OUTCOME ASSESSMENT;
PRIMARY PREVENTION;
PROTEIN BLOOD LEVEL;
RISK REDUCTION;
TREATMENT DURATION;
UNSTABLE ANGINA PECTORIS;
AGED;
BLOOD;
CARDIOLOGY;
CARDIOVASCULAR DISEASES;
DECISION MAKING;
EVIDENCE BASED MEDICINE;
FEMALE;
MALE;
MIDDLE AGED;
RANDOMIZED CONTROLLED TRIAL (TOPIC);
TRENDS;
AGED;
C-REACTIVE PROTEIN;
CARDIOLOGY;
CARDIOVASCULAR DISEASES;
CHOLESTEROL, LDL;
DECISION MAKING;
EVIDENCE-BASED MEDICINE;
FEMALE;
FLUOROBENZENES;
HUMANS;
HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS;
MALE;
MIDDLE AGED;
PRIMARY PREVENTION;
PYRIMIDINES;
RANDOMIZED CONTROLLED TRIALS AS TOPIC;
SULFONAMIDES;
|
EID: 63149147201
PISSN: 15233782
EISSN: None
Source Type: Journal
DOI: 10.1007/s11886-009-0013-0 Document Type: Note |
Times cited : (5)
|
References (5)
|